Santersus Bio Merger
Xenetic Biosciences agrees to merge with Santersus to create a Nasdaq-listed NET therapies company.
Anonymous
Xenetic Biosciences has agreed to combine with privately held Santersus AG in an all-stock transaction that will create Santersus Bio, a Nasdaq-listed company focused on therapies targeting neutrophil extracellular traps (NETs), which are implicated in critical care, autoimmune disease, transplantation and cancer. Santersus shareholders are expected to own about 85% of the combined company, while existing Xenetic shareholders will hold roughly 15%. The company plans to combine Santersus’ NucleoCapture blood-purification platform with Xenetic’s DNase technology and advance four clinical programs involving sepsis, systemic lupus erythematosus, liver transplantation and a DNase/CAR-T approach for large B-cell lymphoma. The transaction is expected to close in the fourth quarter of 2026, subject to shareholder, regulatory and Nasdaq approvals, with the new entity trading under the ticker SNTS.
Key Points
1
Santersus’ NucleoCapture platform has received two U.S. FDA Breakthrough Device designations: one supporting a pivotal sepsis trial and another supporting a planned pivotal study of systemic lupus erythematosus as a non-immunosuppressive treatment.
2
The transaction is structured as a reverse merger, enabling the privately held Santersus to become publicly traded through its combination with Xenetic rather than pursuing a traditional initial public offering.
3
The companies are targeting a European market launch for the combined company’s therapies in 2028, adding a commercialization milestone beyond the planned merger closing.
4
Santersus’ NucleoCapture platform is expected to enter pivotal liver-transplantation studies aimed at improving graft quality during normothermic machine perfusion, while Xenetic’s DNase program is already being evaluated in a Phase 1b investigator-initiated trial in Israel alongside anti-CD19 CAR-T therapy.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
9
Articles
39
Reach
48
A
AnonymousAuthor
